scholarly journals Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir

2011 ◽  
Vol 39 (6) ◽  
pp. 1070-1078 ◽  
Author(s):  
Brian J. Kirby ◽  
Ann C. Collier ◽  
Evan D. Kharasch ◽  
Dale Whittington ◽  
Kenneth E. Thummel ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Drug Interactions ◽  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors ◽  
Cytochrome P450 3A ◽  
Complex Drug

scholarly journals Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin, or Bupropion

2011 ◽  
Vol 40 (3) ◽  
pp. 610-616 ◽  
Author(s):  
Brian J. Kirby ◽  
Ann C. Collier ◽  
Evan D. Kharasch ◽  
Dale Whittington ◽  
Kenneth E. Thummel ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors ◽  
Complex Drug

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals

2019 ◽  
Vol 221 (2) ◽  
pp. 223-231 ◽  
Author(s):  
Matthew P Kosloski ◽  
Rajneet Oberoi ◽  
Stanley Wang ◽  
Rolando M Viani ◽  
Armen Asatryan ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Protease Inhibitors ◽  
Drug Exposure ◽  
Phase 1 ◽  
Area Under The Curve ◽  
Careful Consideration ◽  
Hiv Protease ◽  
Fixed Dose ◽  
Hiv Protease Inhibitors ◽  
Clinically Significant

Abstract Background Treatment of patients coinfected with hepatitis C and human immunodeficiency viruses (HCV; HIV) requires careful consideration of potential drug-drug interactions between HCV direct-acting antiviral agents (DAA) and HIV antiretrovirals. Glecaprevir/pibrentasvir is a fixed-dose combination of an NS3/4A protease inhibitor and an NS5A inhibitor approved for the treatment of chronic HCV genotype 1–6 infection, including patients with HIV coinfection. Methods A series of phase 1 studies was conducted to evaluate potential interactions of glecaprevir and pibrentasvir with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, abacavir/dolutegravir/lamivudine, raltegravir, rilpivirine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate. Pharmacokinetics of the antiretrovirals and DAAs were characterized when administered alone and in combination to quantify changes in systemic drug exposure. Results Glecaprevir area under the curve increased >4-fold in the presence of ritonavir-boosted HIV protease inhibitors, while pibrentasvir concentrations were not significantly affected; elevations in alanine transaminase occurred in combination with atazanavir/ritonavir only. Exposures of glecaprevir and pibrentasvir may be significantly decreased by efavirenz. Coadministration with glecaprevir and pibrentasvir did not result in clinically significant changes in the exposure of any antiretroviral agents. Conclusions Atazanavir is contraindicated with glecaprevir/pibrentasvir and use of boosted protease inhibitors or efavirenz is not recommended. No clinically significant interactions were observed with other studied antiretrovirals.

Drug Interactions of HIV Protease Inhibitors

Drug Safety ◽  
1999 ◽  
Vol 20 (2) ◽  
pp. 147-169 ◽  
Author(s):  
Lisa I. Malaty ◽  
Jeffrey J. Kuper
Keyword(s):  
Drug Interactions ◽  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors
Sign in / Sign up

Export Citation Format

Share Document